NTLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Intellia Therapeutics Inc (NTLA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as the FDA lifting the clinical hold on Nex-Z and increased analyst price targets, the company's financial performance remains weak with significant net income losses and declining EPS. Additionally, insider selling and the lack of strong technical or proprietary trading signals suggest caution. A 'hold' is recommended until further positive developments or stronger financial performance are observed.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 36.623, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 11.243, with resistance at 13.561. Overall, the technical indicators suggest a weak trend with no strong buy signal.
FDA lifted the clinical hold on Nex-Z, boosting market confidence.
Analysts have raised price targets, with one firm increasing the probability of approval for Nex-Z to 35%.
Revenue grew 51.27% YoY in Q3 2025.
Insiders are selling heavily, with a 2235.78% increase in selling activity over the last month.
Net income and EPS are declining significantly, with net income down -25.34% YoY and EPS down -31.34% YoY.
The stock is trading below its pivot point and shows bearish technical indicators.
In Q3 2025, revenue increased by 51.27% YoY to $13.78M, but net income dropped to -$101.32M (-25.34% YoY), and EPS declined to -0.92 (-31.34% YoY). Gross margin remained stable at 100%. The company is still operating at a significant loss, which raises concerns about its financial health.
Analysts have mixed views. Baird raised its price target to $7 with a Neutral rating, while H.C. Wainwright increased its target to $25 with a Buy rating, citing manageable clinical risks. Citizens reiterated an Outperform rating with a $21 target, highlighting a valuation disconnect. BofA lowered its target to $12, maintaining a Neutral rating, citing broader biotech sector trends.
